March 24, 2017
New lab-on-a-chip platform seeks to improve pathogen detection
Researchers from the Fraunhofer Institute have developed a new prototype lab-on-a-chip platform for the easy and versatile detection of molecular pathogens.
Nuclear amplification testing is commonly used for pathogen detection; however, the process is currently manually intensive and complex, and requires dedicated equipment. This prevents its use in some settings, and pathogen detection in individual samples.
In a bid to solve these issues, Natalia Sandetskaya and colleagues at the Fraunhofer Institute for Cell Therapy & Immunology (Leipzig, Germany) have developed a prototype lab-on-a-chip platform capable of automating the process in a single instrument.
“We were motivated by the existing need for making the molecular analysis of complex samples much simpler for the users,” commented Sandetskaya. “Our particular applied interest is the detection of the pathogens in blood; for instance in sepsis, when only a few microorganisms must be rapidly found in a large volume of blood.”
The chip utilizes microfluidics and integrates sample volume transition, lysis, nucleic acid isolation, amplification (PCR or LAMP), and real-time fluorescence detection. As a single instrument, it could enable diagnostics in situations not previously feasible.
The researchers go on to demonstrate its proof-of-concept in the detection of E. coli and Salmonella bacterial species.
“Although our current prototype of the platform will need further development for this application, we have already demonstrated a high level of integration of very diverse processes without making the system overly complex,” noted Sandetskaya.
The team is now planning experiments to evaluate the platform in real-world samples and perfect its design.
The full article “An integrated versatile lab-on-a-chip platform for the isolation and nucleic acid-based detection of pathogens” is available open access at: http://www.future-science.com/doi/full/10.4155/fsoa-2016-0088
About Future Science OA
Launched in March 2015, Future Science OA is the inaugural gold open access journal from Future Science Group. It publishes articles covering research of application to human health, and utilizes a CC-BY license. Future Science OA embraces the importance of publishing all good-quality research with the potential to further the progress of medical science. Negative and early-phase research will be considered. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.